Navigation Links
Anacor Pharmaceuticals Appoints Dr. Kurt Jarnagin Vice President of Biological Research
Date:8/4/2008

PALO ALTO, Calif., Aug. 4 /PRNewswire/ -- Anacor Pharmaceuticals announced today that it has appointed Kurt Jarnagin, Ph.D., as its Vice President of Biological Research.

"We are pleased to welcome Kurt to the company," said Jacob Plattner, Ph.D., Senior Vice President of Research at Anacor Pharmaceuticals. "Kurt is a noted expert in the field of small molecule drugs involved in inflammation and his expertise will enrich our team as we continue to expand our pipeline fed by our boron chemistry platform."

Previously, Dr. Jarnagin was with Iconix Pharmaceuticals, Inc., serving as Vice President of Biology and Chemogenomics and Vice President of New Technology and Translational Medicine from 1998 to 2007. Dr. Jarnagin also held research leadership roles at Roche Pharmaceuticals (Palo Alto) from 1994 to 1998 and at Syntex Research, a specialty pharmaceutical company acquired by Roche, from 1986 to 1994.

At Iconix he directed the development of the DrugMatrix and ToxFX products -- tools and decision-making resources that aid scientists in the selection and prioritization of novel drugs. At Roche and Syntex he focused on drug discovery, targeting receptors and enzymes involved in inflammation, arthritis and asthma. Dr. Jarnagin was awarded the Fry-E. Werele International Kinin Chemistry Prize for work in the bradykinin field. He is the author of numerous peer-reviewed scientific papers and has several granted patents.

Dr. Jarnagin carried out highly cited studies of the insulin receptor at the Hormone Research Institute of the University of California, San Francisco. He received his Ph.D. in Biochemistry from the University of Wisconsin, Madison, and holds a B.S. in Biochemistry from North Carolina State University in Raleigh.

About Anacor Pharmaceuticals

Anacor is a biopharmaceutical company developing novel small molecule therapeutics derived from its boron chemistry platform. Anacor has focused initially on developing topical applications of its compounds to treat fungal, bacterial and inflammatory diseases. Anacor's most advanced product candidate is AN2690, a novel topical antifungal in development for the treatment of toenail onychomycosis, which is a fungal infection of the nail and nail bed. AN2690 is licensed to Schering-Plough under a worldwide development and commercialization agreement for all indications including the treatment of onychomycosis. Anacor also has a research and development collaboration with GlaxoSmithKline for the discovery, development, manufacture and worldwide commercialization of novel systemic therapeutics for viral and bacterial diseases utilizing Anacor's boron-based chemistry. For more information visit http://www.anacor.com.


'/>"/>
SOURCE Anacor Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Anacor to Present Clinical and Preclinical Data on Topical Anti-Inflammatory Candidates, AN2728 and AN2898, at the International Investigative Dermatology 2008 Conference
2. GlaxoSmithKline and Anacor Pharmaceuticals Form Alliance to Develop Systemic Antivirals and Antibiotics Based on Boron Chemistry
3. Anacor Files Registration Statement for Initial Public Offering
4. Anadys Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
5. VIA Pharmaceuticals to Present at 13th Annual IBC Life Sciences Drug Discovery & Development of Innovative Therapeutics World Congress
6. Onyx Pharmaceuticals to Present at Bank of America 2008 Specialty Pharmaceuticals Conference
7. Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational Oncology Symposium
8. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
9. Vista Partners Updates Coverage on Raptor Pharmaceuticals Corp. (OTC Bulletin Board: RPTP)
10. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
11. BioCryst Pharmaceuticals To Announce Second Quarter 2008 Financial Results on August 7, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Mass. , March 29, 2017 /PRNewswire/ ... in applying mechanistic modeling to drug research ... their collaboration with Zymeworks Inc. for quantitative ... conjugate therapeutics intended for the treatment of ... supported Zymeworks previously for GLP toxicology studies ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... for cell-based assays, disperses a quarterly travel award to noteworthy scientists who will ... company announced that its new round of awards are being given to two ...
(Date:3/29/2017)... , Mar 29, 2017 Research and ... Market Analysis & Trends - Industry Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the market estimates and forecasts for all the given segments ...
(Date:3/29/2017)... , March 29, 2017 /PRNewswire/ -  GeneNews Limited ... BreastSentry™ , a new risk stratification test for breast ... lab, Innovative Diagnostics Laboratory ("IDL"). BreastSentry incorporates a blood-based biomarker ... and lifetime risk for developing breast cancer.   ... BreastSentry measures the ...
Breaking Biology Technology:
(Date:3/22/2017)... -- Vigilant Solutions , a vehicle location and ... today the appointment of retired FBI special agent ... development. Mr. Sheridan brings more than 21 ... on the aviation transportation sector, to his new role ... served as the Aviation Liaison Agent Coordinator (ALAC) in ...
(Date:3/13/2017)... March 13, 2017 Future of security: Biometric Face Matching ... ... DERMALOGs Face Matching enables to match face pictures against each ... to identify individuals. (PRNewsFoto/Dermalog Identification Systems) ... DERMALOG,s "Face Matching" is the fastest software for biometric Face Matching on ...
(Date:3/7/2017)... , March 7, 2017   HireVue , ... top global companies identify the best talent, faster, today ... Chief Sales Officer (CSO) and Diana Kucer ... round out a seasoned executive team poised to drive continued ... building on a year of record bookings in 2017. ...
Breaking Biology News(10 mins):